Panicker G K, Desai B, Lokhandwala Y
Quintiles ECG Services, Mumbai, India.
Arrhythmia Associates, Mumbai, India.
Heart Asia. 2009 Jan 1;1(1):26-30. doi: 10.1136/ha.2008.000265. eCollection 2009.
The range of implantable cardiac pacing devices has expanded, with the advances in available technology. Indications for cardiac pacing devices, that is pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy devices (CRTs), have expanded for the treatment, diagnosis and monitoring of bradycardia, tachycardia and heart failure. While the need for pacemakers is increasing, not all patients who require pacemakers are receiving them, especially in the Asia-Pacific region. There is a need to be more critical in advising the use of more expensive devices like ICDs and CRT/CRT-D devices, since most patients in the Asia-Pacific region pay out of pocket for these therapies. The AHA-ACC guidelines need not be blindly followed, since they are too wide-sweeping and are often based on the intention-to-treat basis of trials rather than on the parameters of the patients actually enrolled.
随着可用技术的进步,可植入心脏起搏设备的范围不断扩大。心脏起搏设备,即起搏器、植入式心脏复律除颤器(ICD)和心脏再同步治疗设备(CRT),在心动过缓、心动过速和心力衰竭的治疗、诊断和监测方面的应用指征有所扩大。虽然起搏器的需求在增加,但并非所有需要起搏器的患者都能获得,尤其是在亚太地区。在建议使用像ICD和CRT/CRT-D设备这类更昂贵的设备时需要更加审慎,因为亚太地区的大多数患者需要自掏腰包支付这些治疗费用。美国心脏协会(AHA)-美国心脏病学会(ACC)指南不必盲目遵循,因为它们过于宽泛,且往往基于试验的意向性治疗原则,而非实际入组患者的参数。